All You Need to Know About Ryder (R) Rating Upgrade to Strong Buy
Ryder (R) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Why Fast-paced Mover Ryder (R) Is a Great Choice for Value Investors
Ryder (R) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Levi & Korsinsky, LLP Notifies Shareholders of Ryder System, Inc. (R) on Upcoming Claims Deadline in a Class Action Settlement
NEW YORK, NY / ACCESSWIRE / June 25, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Ryder System, Inc. (NYSE: R). The settlement provides for a fund of $45,000,000 to benefit class members.
Is Ryder System (R) Stock Undervalued Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Here's Why Investors Should Retain Ryder (R) Stock Now
Ryder's (R) top line is bolstered by the robust segmental performance. Shareholder-friendly efforts are commendable.
$45,000,000 Recovery from Ryder System, Inc. (R). L&K, LLP Reminds Shareholders to File a Claim Before Deadline
NEW YORK, NY / ACCESSWIRE / June 20, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Ryder System, Inc. (NYSE: R). The settlement provides for a fund of $45,000,000 to benefit class members.
Mace(R) Brand Teams Up with Pyramyd AIR for Outdoor Adventure Protection
CLEVELAND, OH / ACCESSWIRE / June 20, 2024 / Mace Security International (OTCQB:MACE), a globally recognized leader in personal safety products, announces a strategic partnership with Pyramyd AIR, the premier online airgun and outdoor gear store, to provide safety solutions for outdoor enthusiasts. These two Cleveland-area companies aim to equip adventurers with the essential tools and knowledge to stay safe while enjoying the great outdoors.
Rutherrin(R) Repurposes Non-Cancer Drugs for Cancer Therapy
TORONTO, ON / ACCESSWIRE / June 20, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that in preclinical research, it's lead drug formulation, Rutherrin® was able to repurpose non-cancer drugs for cancer therapy. Drug repurposing is the process of finding new uses for existing clinically approved drugs.
Rutherrin(R) Demonstrates Complete Response in Lung Cancer Preclinically
TORONTO, ON / ACCESSWIRE / June 19, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that it's lead drug formulation, Rutherrin®, has demonstrated an ability to provide a complete response in a Non-Small Cell Lung Cancer ("NSCLC") animal model. Theralase® recently press released its latest research, using a well-established Lewis Lung Cancer ("LLC1") orthotopic model, representing NSCLC.
Ryder System, Inc. (R) Shareholders - L&K, LLP Encourages you to File a Claim Against the Settlement Fund Before Deadline
NEW YORK, NY / ACCESSWIRE / June 18, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class action lawsuit against Ryder System, Inc. (NYSE: R). The settlement provides for a fund of $45,000,000 to benefit class members.
Rutherrin(R) Increases Efficacy of Immunotherapy Preclinically
TORONTO, ON / ACCESSWIRE / June 18, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations, intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that in preclinical research, it's lead drug formulation, Rutherrin®, has demonstrated an ability to increase the efficacy of immunotherapy. Immunotherapy, the latest technology in the war on cancer, can come in various forms; including: checkpoint inhibitors, Chimeric Antigen Receptor ("CAR") T-Cell therapy, cytokines, immunomodulators, cancer vaccines, monoclonal antibodies and oncolytic viruses, but the fundamental Mechanism Of Action ("MOA") of all of these immunogenic drugs is to stimulate the immune system to destroy cancer cells.
Rutherrin(R) Increases Efficacy of Chemotherapy
TORONTO, ON / ACCESSWIRE / June 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light and/or radiation activated small molecules and their formulations intended for the safe and effective destruction of various cancers, bacteria and viruses, is pleased to announce that in preclinical research, it's lead drug formulation, Rutherrin® has been proven effective in increasing the efficacy of chemotherapy and reducing multidrug resistance. Chemotherapy is currently one of the principal treatment methods for cancer, along with radiation and surgery.
